<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03074201</url>
  </required_header>
  <id_info>
    <org_study_id>32194</org_study_id>
    <nct_id>NCT03074201</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of the Ability of Spyglass Cholangioscopy to Facilitate Radiation Free ERCP</brief_title>
  <official_title>Prospective Evaluation of the Ability of Spyglass Cholangioscopy to Facilitate Radiation Free ERCP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Evaluation of the Ability of Spyglass Cholangioscopy to Facilitate Radiation Free
      ERCP for non-complex bile duct stone disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2015</start_date>
  <completion_date type="Actual">May 20, 2017</completion_date>
  <primary_completion_date type="Actual">May 20, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective feasibility study to evaluate potential for cholangioscopy to facilitate radiation-free ERCP.</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stone clearance</measure>
    <time_frame>During the cholangioscopy procedure</time_frame>
    <description>Successful clearance of stones from the bile duct using cholangioscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure Duration</measure>
    <time_frame>5 minutes to 2.5 hours anticipated time frame</time_frame>
    <description>Duration of procedure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to 30 weeks post-procedure</time_frame>
    <description>Evaluation of adverse events following the procedure</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Choledocholithiasis</condition>
  <condition>Biliary Obstruction</condition>
  <arm_group>
    <arm_group_label>Cholangioscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm undergo radiation-free ERCP facilitated by cholangioscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cholangioscopy</intervention_name>
    <description>Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.</description>
    <arm_group_label>Cholangioscopy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spyglass DS Cholangioscope</intervention_name>
    <description>Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.</description>
    <arm_group_label>Cholangioscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 and above

          2. Non-complex biliary stone disease involving stones in the common bile or common
             hepatic duct.

          3. Patient has undergone non-invasive imaging (abdo US, MRCP etc) which clearly
             delineates bile duct diameter and suggests non complex biliary stone disease.

          4. Willing and able to comply with the study procedures and provide written informed
             consent to participate in the study.

        Exclusion Criteria:

          1. Age &lt;18

          2. Potentially vulnerable subjects including, homeless people, pregnant females,
             employees and students.

          3. Participation in another related investigational study that could affect the results
             of this study within the previous 30 days

          4. Complex biliary stone disease cases with unusual location of the stones (intra
             hepatic, cystic duct, stone proximal to bile duct stricture)

          5. Known bile duct infection (cholangitis defined as ongoing fevers on the day of the
             ERCP procedure or purulence evident at the ampulla or bile duct on
             cannulation/sphincterotomy. If clear bile is aspirated during the study procedure, we
             will proceed according to study procedures. If purulence is detected upon aspiration
             of bile during the procedure, patient will be excluded from the study and undergo
             standard radiation-based ERCP rather than cholangioscopy.)

        5) Complex post-surgical anatomy e.g. Billroth type II anatomy, Roux-en-Y-gastrojejunostomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2017</study_first_posted>
  <last_update_submitted>September 8, 2018</last_update_submitted>
  <last_update_submitted_qc>September 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Subhas Banerjee</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>ERCP, choledocholithiasis, cholangioscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choledocholithiasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

